Thermo Fisher Scientific Sails Through Q3 With Mixed Earnings, CEO Says In Great Position To Deliver 2024 Objectives

On Wednesday, Thermo Fisher Scientific Inc. (NYSE: TMO) posted third-quarter revenue of $10.59 billion, almost flat year over year, marginally missing the consensus of $10.64 billion.

Revenue growth, organic revenue growth, and core organic revenue all improved sequentially from Q2 and were flat compared to the prior-year quarter.

Revenue from the Life Sciences Solutions Segment declined by 1.9% to $2.39 billion. Analytical Instruments Segment sales were up 3.1% to $1.81 billion. 

Also Read: Novo Nordisk/AstraZeneca’s Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses.

Specialty Diagnostics Segment revenues ...